Group One Trading’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Group One Trading’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,200	Closed	-$19K	–	9056
2021 Q4	$19K	Buy	7,200 +3,200	+80%	+$9.67K	﹤0.01%	7023
2021 Q3	$12K	Sell	4,000 -10,100	-72%	-$33.7K	﹤0.01%	7439
2021 Q2	$52K	Buy	14,100 +13,700	+3,425%	+$45.6K	﹤0.01%	6551
2021 Q1	$1K	Buy	400 +200	+100%	+$812	﹤0.01%	7500
2020 Q4	$1K	Sell	200 -500	-71%	-$1.79K	﹤0.01%	6378
2020 Q3	$2K	Sell	700 -5,800	-89%	-$23.4K	﹤0.01%	5870
2020 Q2	$30K	Buy	+6,500	New	+$28.8K	﹤0.01%	4645

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Group One Trading's PHAS Position: Q4 2021 in Review

Group One Trading sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2021, closing a stake of 1,700 shares — an estimated $5.14K sold.

Group One Trading first reported a position in PHAS in Q4 2020 and held it in 4 quarters. The position peaked at $5K in Q3 2021. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2021.

Group One Trading reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Group One Trading sold 1,700 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $5.14K.
Group One Trading first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Group One Trading's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $5K in Q3 2021.
51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Group One Trading's 13F filing for Q4 2021, filed 11 Feb 2022.